UNCY News and Press, Unicycive Therapeutics Inc. From 06/06/22

LOS ALTOS, Calif., June 06, 2022 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, today announced that Shalabh Gupta, M.D., Chief Executive Officer of Unicycive, will participa...

LOS ALTOS, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease today announced the initiation of its pivotal clinical bioequivalence (BE) study of Renazorb&#x...

NEW YORK, NY / ACCESSWIRE / May 24, 2022 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid cap publicly traded companies recently issued a new C-Level interview with Unicycive Therapeutics. Mark Roberts, Senior Editor at Traders N...

Unicycive Therapeutics press release (NASDAQ:UNCY): Q1 GAAP EPS of -$0.24 misses by $0.07. As of March 31, 2022, cash and cash equivalents totaled $13.6 million, which the Company believes is sufficient to support it through to several milestones, including the completion of the NDA submissio...

On track to initiate clinical bioequivalence study of Renazorb to treat hyperphosphatemia in healthy volunteers in second quarter 2022 Plans to initiate Phase 1 study for UNI-494 in second half of 2022 LOS ALTOS, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- Unicycive Therapeut...

Glancy Prongay & Murray LLP (“GPM”) announces its investigation of Unicycive Therapeutics, Inc. (Nasdaq: UNCY) concerning the Company and its directors’ and officers’ possible violations of state laws. If you own Unicycive stock, would like to learn m...

LOS ALTOS, Calif., April 14, 2022 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, today announced that there will be a Key Opinion Leader (KOL) Event discussing “Novel ...

Unicycive Therapeutics press release (NASDAQ:UNCY): FY GAAP EPS of $0.86. FY Cash and cash equivalents of $16.6M For further details see: Unicycive Therapeutics GAAP EPS of $0.86

On track to initiate clinical bioequivalence study of Renazorb to treat hyperphosphatemia in healthy volunteers in first half of 2022 Plans to initiate Phase 1 study for UNI-494 in second half of 2022 LOS ALTOS, Calif., March 31, 2022 (GLOBE NEWSWIRE) -- Unicycive Therapeuti...

LOS ALTOS, Calif., March 23, 2022 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, today announced that the Unicycive team, together with the Company’s Chief Executive O...